Competition getting stiff for DPP-4 inhibitors

Published: 2011-09-30 06:57:00
Updated: 2011-09-30 06:57:00
Following Bristol-Myers Squibb’s Onglyza (saxagliptin), Boehringer Ingelheim finally won the approval of the Korea Food and Drug Administration for their diabetes drug Trajenta (linagliptin), a dipeptidyl peptidase 4 (DPP-4) inhibitor that will directly compete with Merck's fast-growing treatment...

Fees

- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.



Most Read News


TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.